Monday, February 23, 2009

The European Commission Approves Efient (prasugrel

No, not Effient (which is the proposed US tradename). Efient (prasugrel) has been approved in Europe for acute coronary syndrome (ACS) patients undergoing PCI. The annoucement was made by Daiichi Sankyo Company, Limited and Eli Lilly and Company.

Two of the major prasugrel studies are:
  • TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction), and
  • TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes),
Prasugrel is a dihydropyridine that is currently under FDA review. The other dihydropyridine you're probably familiar with is Plavix (clopidogrel) which is marketed by sanofi-aventis U.S. LLC and Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

No comments:

Post a Comment

Blog Widget by LinkWithin